Abstract
Cardiovascular Disease (CVD) is one of the most important causes of morbidity and mortality, and associated with an important economic burden globally. Over the last decade, the prevalence of CVD has been rising globally, and is now associated with millions of death annually in both developed and developing countries. There is good evidence that the immune system is involved in the pathophysiology of CVD. Toll-like receptors (TLRs) and their down-stream signaling pathways play an important role in the immune system. Recent studies have suggested that the TLRs are involved in atherogenesis, including stroke, myocardial infarction, ischemiareperfusion injury, cardiac remodeling and development of Heart Failure (HF). In this review we have summarized the recent studies investigating the role of TLRs in CVD and the potential for using TLRs signaling pathways as a therapeutic target in CVD.
Keywords: Cardiovascular disease, immune system, Toll-like receptors, signaling pathway, atherogenesis, stroke.
Current Pharmaceutical Design
Title:Toll-like Receptors Signaling Pathways as a Potential Therapeutic Target in Cardiovascular Disease
Volume: 24 Issue: 17
Author(s): Seyed Mostafa Parizadeh, Maryam Ghandehari, Motahareh Heydari-majd, Sima Seifi, Ramin Mardani, Seyed Mohamadreza Parizadeh, Majid Ghayour-Mobarhan, Gordon A. Ferns, Seyed Mahdi Hassanian*Amir Avan*
Affiliation:
- Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad,Iran
- Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad,Iran
Keywords: Cardiovascular disease, immune system, Toll-like receptors, signaling pathway, atherogenesis, stroke.
Abstract: Cardiovascular Disease (CVD) is one of the most important causes of morbidity and mortality, and associated with an important economic burden globally. Over the last decade, the prevalence of CVD has been rising globally, and is now associated with millions of death annually in both developed and developing countries. There is good evidence that the immune system is involved in the pathophysiology of CVD. Toll-like receptors (TLRs) and their down-stream signaling pathways play an important role in the immune system. Recent studies have suggested that the TLRs are involved in atherogenesis, including stroke, myocardial infarction, ischemiareperfusion injury, cardiac remodeling and development of Heart Failure (HF). In this review we have summarized the recent studies investigating the role of TLRs in CVD and the potential for using TLRs signaling pathways as a therapeutic target in CVD.
Export Options
About this article
Cite this article as:
Parizadeh Mostafa Seyed , Ghandehari Maryam , Heydari-majd Motahareh , Seifi Sima , Mardani Ramin , Parizadeh Mohamadreza Seyed , Ghayour-Mobarhan Majid , Ferns A. Gordon , Hassanian Mahdi Seyed *, Avan Amir *, Toll-like Receptors Signaling Pathways as a Potential Therapeutic Target in Cardiovascular Disease, Current Pharmaceutical Design 2018; 24 (17) . https://dx.doi.org/10.2174/1381612824666180614090224
DOI https://dx.doi.org/10.2174/1381612824666180614090224 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ryanodine Receptor Patents
Recent Patents on Biotechnology Conserved Domains, Residues, WebLogo and Active Sites of Caspase- Cascades Related to Apoptotic Signaling Pathway
Current Bioinformatics Thyroid Hormones and Cardiovascular System: From Bench to Bedside
Current Drug Therapy Historical Aspects and Relevance of the Human Coronary Collateral Circulation
Current Cardiology Reviews Molecular Imaging of Matrix Metalloproteinases In Vivo Using Small Molecule Inhibitors for SPECT and PET
Current Medicinal Chemistry Matrix Metalloproteinase Inhibitors as Prospective Agents for the Prevention and Treatment of Cardiovascular and Neoplastic Diseases
Current Topics in Medicinal Chemistry Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research Stem Cell Regenerative Potential Combined with Nanotechnology and Tissue Engineering for Myocardial Regeneration
Current Stem Cell Research & Therapy CYP24A1 as a Potential Target for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry NAD in Skin: Therapeutic Approaches for Niacin
Current Pharmaceutical Design Genetic Polymorphism of LDLR (rs688) is Associated with Primary Intracerebral Hemorrhage
Current Neurovascular Research Natriuretic Peptide Family: New Aspects
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Pulmonary Embolism Response Team (PERT) - A New Paradigm for the Treatment of Pulmonary Embolism
Current Pharmaceutical Design Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Barbituric Acids in Organic Transformations, An Outlook to the Reaction Media
Mini-Reviews in Organic Chemistry New Insight into Urate-Related Mechanism of Cardiovascular Damage
Current Pharmaceutical Design Phase 4 Studies in Heart Failure - What is Done and What is Needed?
Current Cardiology Reviews The Etiology of Hypertension in the Metabolic Syndrome Part Three: The Regulation and Dysregulation of Blood Pressure
Current Vascular Pharmacology Current Approaches to Prevention of Contrast Induced Acute Kidney Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Cytotoxic Properties of Clofibrate and other Peroxisome Proliferators: Relevance to Cancer Progression
Current Medicinal Chemistry